Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus carboplatin versus paclitaxel plus carboplatin as first-line chemotherapy for advanced ovarian cancer
ChiCTR2000034944Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel and carboplatin in ovarian cancer and fallopian tube cancer (PFTC) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Objective response rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2000034944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034944.